JP2022543021A5 - - Google Patents
Info
- Publication number
- JP2022543021A5 JP2022543021A5 JP2022506342A JP2022506342A JP2022543021A5 JP 2022543021 A5 JP2022543021 A5 JP 2022543021A5 JP 2022506342 A JP2022506342 A JP 2022506342A JP 2022506342 A JP2022506342 A JP 2022506342A JP 2022543021 A5 JP2022543021 A5 JP 2022543021A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- tak
- administration
- treatment
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025093180A JP2025143272A (ja) | 2019-05-29 | 2025-06-04 | がんを処置する方法及び使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962853842P | 2019-05-29 | 2019-05-29 | |
| US62/853,842 | 2019-05-29 | ||
| PCT/US2020/070080 WO2020243745A1 (en) | 2019-05-29 | 2020-05-28 | Methods and uses for treating cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025093180A Division JP2025143272A (ja) | 2019-05-29 | 2025-06-04 | がんを処置する方法及び使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022543021A JP2022543021A (ja) | 2022-10-07 |
| JP2022543021A5 true JP2022543021A5 (https=) | 2023-06-06 |
Family
ID=73553943
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022506342A Pending JP2022543021A (ja) | 2019-05-29 | 2020-05-28 | がんを処置する方法及び使用 |
| JP2025093180A Pending JP2025143272A (ja) | 2019-05-29 | 2025-06-04 | がんを処置する方法及び使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025093180A Pending JP2025143272A (ja) | 2019-05-29 | 2025-06-04 | がんを処置する方法及び使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11911374B2 (https=) |
| EP (1) | EP3976036A4 (https=) |
| JP (2) | JP2022543021A (https=) |
| KR (1) | KR20220002745A (https=) |
| CN (2) | CN119326899A (https=) |
| AU (1) | AU2020283913A1 (https=) |
| BR (1) | BR112021026294A2 (https=) |
| CA (1) | CA3141072A1 (https=) |
| IL (1) | IL288591B1 (https=) |
| MX (1) | MX2021014686A (https=) |
| WO (1) | WO2020243745A1 (https=) |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170326118A1 (en) * | 2001-07-02 | 2017-11-16 | Sinan Tas | Drug treatment of tumors wherein hedgehog/smoothened signaling is utilized for inhibition of apoptosis of tumor cells |
| NZ587719A (en) * | 2008-02-26 | 2012-04-27 | Takeda Pharmaceutical | Fused heterocyclic derivative and use thereof |
| EP3103452A1 (en) * | 2009-08-25 | 2016-12-14 | Abraxis BioScience, LLC | Combination therapy with nanoparticle compositions of taxane and hedgehog inhibitors |
| JP6031437B2 (ja) | 2010-06-07 | 2016-11-24 | アブラクシス バイオサイエンス， エルエルシー | 増殖性疾患を処置するための組み合わせ療法 |
| JP2012097032A (ja) * | 2010-11-02 | 2012-05-24 | Takeda Chem Ind Ltd | 併用医薬 |
| WO2014165644A2 (en) * | 2013-04-04 | 2014-10-09 | The General Hospital Corporation | Combination treatments with sonic hedgehog inhibitors |
| WO2015073691A1 (en) * | 2013-11-14 | 2015-05-21 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for treating cancer by activation of bmp signaling |
| US10329304B2 (en) * | 2014-09-12 | 2019-06-25 | Vanderbilt University | Compounds and methods for inhibition of hedgehog signaling and phosphodiesterase |
| US10787640B2 (en) * | 2015-03-03 | 2020-09-29 | The Board Of Trustees Of The Leland Stanford Junior University | Producing mesodermal cell types and methods of using the same |
| US11026889B2 (en) * | 2015-12-09 | 2021-06-08 | Board Of Regents, The University Of Texas System | Polymeric drug delivery systems for treatment of disease |
| CN108853507A (zh) * | 2017-05-11 | 2018-11-23 | 复旦大学 | 一种抗肿瘤的增效药物组合物及其制备方法和用途 |
| US20200368246A1 (en) * | 2017-11-17 | 2020-11-26 | Jaeyoung Yoon | Combination therapy targeting cancer associated with the hedgehog pathway |
-
2020
- 2020-05-28 MX MX2021014686A patent/MX2021014686A/es unknown
- 2020-05-28 BR BR112021026294A patent/BR112021026294A2/pt unknown
- 2020-05-28 CA CA3141072A patent/CA3141072A1/en active Pending
- 2020-05-28 WO PCT/US2020/070080 patent/WO2020243745A1/en not_active Ceased
- 2020-05-28 CN CN202410646745.9A patent/CN119326899A/zh active Pending
- 2020-05-28 EP EP20814240.6A patent/EP3976036A4/en active Pending
- 2020-05-28 AU AU2020283913A patent/AU2020283913A1/en not_active Abandoned
- 2020-05-28 KR KR1020217042915A patent/KR20220002745A/ko active Pending
- 2020-05-28 CN CN202080050914.2A patent/CN114126656A/zh active Pending
- 2020-05-28 JP JP2022506342A patent/JP2022543021A/ja active Pending
-
2021
- 2021-01-20 US US17/153,345 patent/US11911374B2/en active Active
- 2021-12-01 IL IL288591A patent/IL288591B1/en unknown
-
2025
- 2025-06-04 JP JP2025093180A patent/JP2025143272A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7332293B2 (ja) | バルリチニブおよび抗癌剤を含んでなる併用療法 | |
| Higuchi et al. | Definitive chemoradiation therapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) in advanced esophageal cancer: a phase 2 trial (KDOG 0501-P2) | |
| JP2010514787A5 (https=) | ||
| JP2019530752A (ja) | がんを治療するための薬物の調製における、抗ｐｄ‐１抗体とｖｅｇｆｒ阻害剤とを組み合わせた使用 | |
| JP2016536352A5 (https=) | ||
| Park et al. | Phase II, multicentre, randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER2-negative metastatic breast cancer | |
| JP2021522193A5 (https=) | ||
| FI3463345T3 (fi) | Farmaseuttisia yhdistelmiä | |
| JPWO2020111018A5 (https=) | ||
| JP2016515586A5 (https=) | ||
| JP2019506392A5 (https=) | ||
| JP2019038796A5 (https=) | ||
| JP2024524461A5 (https=) | ||
| EP2164573A1 (en) | Cancer treatment combination therapy comprising vinflunine and trastuzumab | |
| WO2017184086A1 (en) | Method of treating liver cancer | |
| Font et al. | Weekly docetaxel with concomitant radiotherapy in patients with inoperable oesophageal cancer | |
| JP2021511344A5 (https=) | ||
| Tanaka et al. | Second-line combination chemotherapy with docetaxel for cisplatin-pretreated refractory metastatic esophageal cancer: a preliminary report of initial experience | |
| Afranie-Sakyi et al. | The toxicity of anti-VEGF agents when coupled with standard chemotherapeutics | |
| JP2006528696A (ja) | 抗癌剤の抗腫瘍活性を増強する方法 | |
| Hahn et al. | Metronomic oral paclitaxel shows anti-tumor effects in an orthotopic mouse model of ovarian cancer | |
| JP2022543021A5 (https=) | ||
| JP2023517671A5 (https=) | ||
| JP2023522325A5 (https=) | ||
| Fujitani et al. | Phase I and pharmacokinetic study of S-1 combined with weekly paclitaxel in patients with advanced gastric cancer |